CARDIO-SELECTIVE BETA-ADRENOBLOCKER SAFETY IN CARDIOVASCULAR DISEASE TREATMENT AMONG PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Abstract

The review is focused on the use of cardio-selective beta-adrenoblockers (BAB) in patients with cardiovascular disease combined with chronic obstructive pulmonary disease (COPD). The data of meta-analyses, clinical trials and reviews are presented, which demonstrate cardio-selective BAB safety in COPD patients. In addition, all-cause and cardiovascular mortality in COPD patients, as well as cardio-selective BAB effects on these mortality parameters, are discussed.

Keywords

• chronic obstructive pulmonary disease
• asthma
• cardiovascular morbidity and mortality
• cardio-selective beta-adrenoblockers
• safety
• fev1